Massey Cancer Center (MCC) at Virginia Commonwealth University (VCU) brings together faculty across the university to foster interdisciplinary and transdisciplinary research strategies aimed at prevention, control, and ultimately the cure of cancer through translation of basic, clinical, and population science. The overall goal of research at MCC is to improve the health and lives of individuals affected by or at risk for cancer, with a particular focus on the high cancer burden in the MCC catchment area, which has a high percentage of underserved and minority populations. Collaborative research is conducted both within and among the 4 scientific programs in Cancer Cell Signaling, Cancer Molecular Genetics, Developmental Therapeutics, and Cancer Prevention and Control, as well as through cross-cutting scientific themes. As a matrix cancer center organized within the VCU Health Sciences division, MCC promotes collaborative research among faculty in the schools of medicine, nursing, dentistry, and pharmacy. Translational research is facilitated through disease- specific focus groups that engage basic, clinical, and prevention and control researchers, as well as clinical care providers. MCC also engages members from the schools of engineering, humanities and sciences, and social work to maximize transdisciplinary research collaborations. Developmental funds are used to support the initial research endeavors of newly recruited faculty and to encourage innovative collaborative research through peer-reviewed pilot research grants that require at least 2 collaborating investigators. To give members access to new technologies and high-quality methodologies and to facilitate successful research, MCC supports 7 shared resources: Microscopy, Lipidomics and Metabolomics, Flow Cytometry, Biostatistics, Cancer Informatics, Tissue and Data Acquisition and Analysis, and Transgenic Mouse. To accelerate translation and dissemination of research findings, MCC supports a full-service Clinical Trials Office that coordinates movement of programmatic scientific concepts through multidisciplinary and disease-specific focus groups into early-phase clinical trials and supports high-priority NCI-sponsored trials. Both clinical trials and cancer care delivery research are extended to greater Virginia through a Minority Based NCI Community Oncology Research Program (MU-NCORP). MCC members currently hold over $36 million in NCI-recognized peer-reviewed (> 35% NCI) funding and of the 158 grants in the portfolio, 106 (56%) are highly cancer specific. The research highlighted in this application stems from 1700 member publications in peer-reviewed journals (~14% of which appear in journals with impact factors of 8 and above since 2012). The upward trajectory of high-impact peer-reviewed collaborative research, guided by center strategic planning and evaluation, illustrates the effectiveness of MCC senior leadership in organizing and coordinating the faculty and resources of VCU to focus them on resolving cancer-related problems.

Public Health Relevance

The mission of Massey Cancer Center is to serve Virginia and the nation as an internationally recognized comprehensive research and treatment center dedicated to improving the quality of human life by eliminating suffering and death through development and delivery of more effective means for the detection, treatment, prevention, control and ultimate cure of cancer. The core of this mission is to facilitate interdisciplinary and trans-disciplinary cancer research so as to harness the considerable intellectual talent and scientific resources of VCU and focus them on solving the nation?s cancer problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-36S2
Application #
9378865
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1995-12-01
Project End
2022-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
36
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Yamada, Akimitsu; Nagahashi, Masayuki; Aoyagi, Tomoyoshi et al. (2018) ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. Mol Cancer Res 16:1059-1070
Cantwell, Marc T; Farrar, Jared S; Lownik, Joseph C et al. (2018) STAT3 suppresses Wnt/?-catenin signaling during the induction phase of primary Myf5+ brown adipogenesis. Cytokine 111:434-444
Aqbi, Hussein F; Wallace, Matthew; Sappal, Samay et al. (2018) IFN-? orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol :
Volker, Sonja E; Hedrick, Shannon E; Feeney, Yvonne B et al. (2018) Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Res 78:3877-3887
Li, Xiaojiaoyang; Liu, Runping; Huang, Zhiming et al. (2018) Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 68:599-615
Durant, Stephen T; Zheng, Li; Wang, Yingchun et al. (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719
Damle, S R; Martin, R K; Cockburn, C L et al. (2018) ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production. Allergy 73:125-136
Wang, Feng; Li, Hongyan; Markovsky, Ela et al. (2018) Pazopanib radio-sensitization of human sarcoma tumors. Oncotarget 9:9311-9324
Stokes, Nancy A; Stanciu, Cristina E; Brocato, Emily R et al. (2018) Simplification of complex DNA profiles using front end cell separation and probabilistic modeling. Forensic Sci Int Genet 36:205-212
Poklepovic, Andrew; Qu, Yuesheng; Dickinson, Molly et al. (2018) Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology 4:

Showing the most recent 10 out of 586 publications